4563 AnGes
- 46
- 00.00%
AnGes News
Anges --- Co-developed Tie2 receptor agonist (AV-001) has obtained fast track designation from the US FDA
Anges ＜4563＞ announced on the 29th that the treatment drug “Tie2 receptor agonist (AV-001)” for acute respiratory distress syndrome (ARDS), which is being jointly developed with Vasomune in the United States, has obtained fast track designation from the US Food and Drug Administration (FDA). ARDS is a condition that causes severe respiratory failure, and there are currently no effective treatments. The FDA's fast track designation indicates that “AV-001” is expected as a therapeutic agent, and this indicates
Material groups, learning aids, etc.
＜156A＞Material Group Co., Ltd. 10X Investment LTD (10X Investment LTD.) Stock Ownership Ratio 11.46% → 10.20% Reporting Obligation Date 2024/04/25 ＜156A＞Material Group Co., Ltd. AP60 Stock Ownership Ratio 35.55% → 31.63% Reporting Obligation Date 2024/04/25 ＜184A＞Learning Aid K & Co., Ltd.
Vasomune Therapeutics Receives US FDA Fast Track Designation for Novel Investigational Medicine AV-001
Fast Track Designation underscores the high unmet medical need for treatment and prevention of acute respiratory distress syndrome (ARDS)TORONTO--(BUSINESS WIRE)--#ARDS--Vasomune Therapeutics, Inc., h
Angers, Linkers, etc.
＜4563＞Anges 1st Unsecured Convertible Bonds Type Stock Acquisition Rights Corporate Bonds (with Convertible Price Amendment Clauses) Number of shares issued from the 13th, 3,925,120 shares ＜5131＞ Linkers downward revisions, operating profit and loss forecast for the current fiscal year △ 197 million yen ← 53 million yen
Emerging Market Stock Digest: Casters temporarily stop high, AI stop high
＜5759＞ Nippon Denkaku 966 -130 continued to drop drastically for 5 days. It has been announced that notes will be added to matters relating to the assumptions of continuing companies in the financial results report for the fiscal year ending 24/3. In the disclosure on the 15th, it was stated that “it has been determined that important uncertainties relating to the assumptions of continuing companies are not recognized,” but as a result of discussions with the accounting auditor, “there is a possibility that it will have an important impact on cash flow based on the high level of loan balances, so there are also important uncertainties relating to the assumptions of continuing enterprises
Notable stock digest (front): Goodcom A, Fuji Electric, Caster, etc.
Ohsho Food ＜9936＞: 8780 yen (+480 yen), a sharp rebound. It was announced that a 1:3 stock split will be implemented with 9/30 as the reference date, and since the stock price level per unit is high, it seems likely that expectations of improved liquidity due to the implementation of the split will increase. Also, shareholder benefits for shareholders at the end of March and the end of September will be substantially expanded by continuing to present preferential vouchers worth 2000 yen to shareholders of 100 shares or more even after the split. Fuji Electric ＜6504＞ :89
Anges--- drastically high, release date for progeria remedy “Zokinvi” decided on the 27th
Significantly higher. It has been announced that the release date of the progeria remedy “Zokinvi” (rare disease drug) has been decided on the 27th. It was included in drug price standards on 4/17. Zokinvi is a treatment for Hutchinson Gilford progeria syndrome (HGPS) and progeroid laminopathy (PL) with poor processing in progeria. It was sold with approval in the US in 20/11, and has also been approved in Europe and the UK. Anges has acquired exclusive sales rights in Japan
Volume change rate ranking (around 9 o'clock) ~ Grosseku, Teikoku Electric, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/24 9:32 as of 9:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate ＜4563＞ Anges 2405500 107185.08 212.21% 0.08
Anges --- Stanford Medical School SLDDDRS Funding Cooperation
Anges ＜4563＞ announced financial cooperation for Stanford University Medical School SLDDDRS on the 15th. The company will strengthen the relationship with the Leland Stanford Stanford Junior University Board of Trustees and Stanford University Medical School's Stanford Laboratory for Drug, Device Development and Regulatory Sciences on 2024/5/15 to strengthen the relationship with Stanford University Medical School
Digital Plus, Genext, etc.
＜3133＞Kaiho Co., Ltd. Yamada Toru Stock Ownership Ratio 12.99% → 14.18% Reporting Obligation Date 2024/04/26 ＜3237＞Intrans Co., Ltd. Intrans LLC Inbound Investment Stock Ownership Ratio 43.50% → 31.27% Reporting Obligation Date 2024/05/08 ＜3491＞GA Technology Co., Ltd. Ryu Higuchi Stock Holding Ratio 43.17% → 42.35% Report
AnGes: Confirmation
AnGes: Quarterly Report - 26th Quarter 1 (2024/01/01 - 2024/03/31)
MonoAI, Hope, etc. [Emerging Markets Press Release]
＜3727＞APLIX earnings forecast revisions, current fiscal year business profit forecast 219 million yen ← 264 million yen ＜4262＞acquisition of shares in Doors, which handles the operation of the Nifty Life exterior wall painting specialty site “Exterior Wall Painting Window,” and making it a subsidiary ＜4563＞Anges 1st Unsecured Convertible Bonds Type Stock Acquisition Rights Corporate Bonds (with conversion price correction clauses) number of shares issued since the 13th, 736,614 shares ＜4579＞LaQuoria Drug Discovery Exterior Wall Remodeling Support Agreement Businesses Consolidated subsidiary that handles it
Anges -- 1Q significant increase in sales, and a lump-sum contract for non-exclusive use rights of OMNI nuclease was recorded as research and development business income
Anges ＜4563＞ announced consolidated financial results for the 1st quarter (24/1/03) of the fiscal year ending 2024/12 on the 10th. Sales increased 584.0% from the same period last year to 113 million yen, operating loss was 2,476 billion yen (loss of 3,036 billion yen in the same period last year), ordinary loss was 1,527 billion yen (loss of 2,897 billion yen), and quarterly net loss attributable to parent company shareholders was 1,824 billion yen (loss of 2,911 billion yen). Business revenue for the first quarter increased significantly compared to the same period last year.
Anges -- recording of non-operating income, non-operating expenses, special profits, extraordinary losses, and corporate tax adjustments
On the 10th, Anges ＜4563＞ announced the recording of non-operating income, non-operating expenses, special profit, extraordinary loss, and corporate tax adjustments for the 1st quarter consolidated cumulative period (2024/1/03) of the fiscal year ending 2024/12. Regarding the recording of non-operating income, an exchange gain of 924 million yen was recorded. Also, of the subsidies that Vasomune, which has signed a joint development agreement, received from the US Department of Defense for continued development of Tie2 receptor agonists (AV-001)
AnGes: Consolidated Financial Results for the 1st Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
Daiwa House, Meiji HD, Shiseido, Sumitomo Electric (10th) (1301-5998)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/10 (Fri) ＜1301＞Kyokuyo ＜1379＞Hokuto ＜1414＞Show Bond ＜1420＞Sanyo H＜1429＞Japan Aqua ＜1431＞Ribwork＜1435＞Robot Home ＜1438＞Gifu Landscaping＜1
Anges --- The transfer destination of Eiger's Zokinvi business has been decided to be Sentynl
Anges ＜4563＞ announced on the 8th that the transfer destination of the “Zokinvi” business of Eiger BioPharmaceuticals (Eiger), which is the manufacturer and seller of “Zokinvi,” which has applied for the application of section 11 of the US Bankruptcy Law, has been decided to be Sentynl Therapeutics (Sentynl). “Zokinvi” is Hutchinson Gilford progeria syndrome, which is infant progeria, and processing failure progeroid laminopathy
Anges --- “AV-001,” a product jointly developed with Vasomune, was presented on a poster at the American Respiratory Society
Anges ＜4563＞ announced on the 7th that Vasomune will present a poster presentation at the American Respiratory Society to be held at the Grand Hyatt in San Diego, California from 2024/5/17 to 22 regarding the therapeutic drug “Tie2 receptor agonist (AV-001)” targeting acute respiratory distress syndrome (ARDS) including viral pneumonia and bacterial pneumonia, which has been jointly developed with Vasomune in the United States . What is the “AV-001”
Ewell, AB & Company, etc.
＜175A＞Wild Smart Co., Ltd. Ishii Yasuhiro Stock Ownership Ratio -% → 6.66% Reporting Obligation Date 2024/04/16 ＜175A＞Will Smart Co., Ltd. Zenrin Stock Ownership Ratio -% → 44.67% Reporting Obligation Occurrence Date 2024/04/16 ＜4563＞Angers Co., Ltd. Canter Fitzgerald Europe (Cantor Fitzgerald Europe) Stock Certificates
Analysis
Price Target
No Data
